Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
據報道，和鉑製藥已在中國開始了用於血液惡性腫瘤的Menin抑制劑HMPL-506的I期臨床試驗。
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients. The lead principal investigators are Dr. Jianxiang Wang and Dr. Hui Wei of Chinese Academy of Medical Sciences Blood Diseases Hospital. Additional details may be found at clinicaltrials.gov, using identifier NCT06387082.
這是一項I期、多中心、開放標籤的臨床研究，旨在評估HMPL-506在血液惡性腫瘤患者中的安全性、藥代動力學和療效。該研究分爲兩個階段，逐漸增加劑量階段和劑量擴張階段。該研究預計招募至少60名患者。首席主要研究員是中國醫學科學院血液病醫院的王建祥醫生和魏輝醫生。更多詳細信息可在clinicaltrials.gov上查找，使用標識符NCT06387082。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。